Company News From Czech Republic
Leciva, a pharmaceutical producer based in the Czech capital Prague, has welcomed the decision of the Slovak National Bank to revalue the Slovak koruna against the Ecu, saying that the move will help its exports to the Slovak market, according to the CTK news agency's Business News.
The company is the largest Slovak medicine importer, with 20% of its total Czech production going to the Slovak market. It has a representative office there.
Leciva sells 70% of its production on the Czech market, in which it has a 33% share. It produces 180 preparations for 250 different medicines, mainly antibiotics, chemotherapy products, antidiabetic drugs, analgesics and vitamins. It recorded a turnover of 3.85 billion koruna ($144.8 million) in 1994.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze